SEC Form 4 · accession 0001209191-16-132663
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen A. Moglia
Officer — VP, Chief Accounting Officer
Period of report
Jul 12, 2016
Accepted (ET)
Jul 14, 2016 · 1:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $4.02 | Jul 12, 2016 | A | 48,000 | A | — | Jul 11, 2026 | Common Stock | 48,000 | 48,000 | D |
| Stock OptionF2,F1 | $15.00 | Jul 12, 2016 | A | 28,800 | A | — | Jul 11, 2026 | Common Stock | 28,800 | 28,800 | D |
Explanation of responses
- F1Thirty-three and one-third percent (33-1/3%) of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the one year anniversary of 07/12/2016, and 1/36 of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month thereafter, so that all of the shares of the stock subject to the option shall be vested on the third (3rd) anniversary of 07/12/2016, subject to the employee's continued service relationship (whether as an employee, director or consultant) with the Corporation or any parent or subsidiary on each such date, as set forth in the applicable stock option grant notice and stock option agreement for such employee.
- F2Not Applicable